Jagsonpal Pharmaceuticals Doubles Q1 Net Profit, Reports Strong Revenue Growth 1 day ago Yesterday
Jagsonpal Pharmaceuticals Ltd announced impressive Q1 financial results. Net profit reached ₹107.00 crore, a 101.89% increase year-over-year and 64.62% increase quarter-over-quarter. Revenue grew to ₹756.00 crore, up 23.13% year-over-year and 29.23% from the previous quarter. The results demonstrate significant growth in both revenue and profitability, indicating improved operational efficiency and strong market performance in the pharmaceutical sector.
Jagsonpal Pharma Reports Q4 Profit Surge, Declares Dividend, and Terminates Business Transfer Agreement May 07, 2025
Jagsonpal Pharma Cancels Acquisition of Resilient as Business Transfer Agreement Terminated May 06, 2025
Jagsonpal Pharmaceuticals Expands Portfolio with ₹24 Crore Acquisition of Resilient Cosmeceuticals' India Business
Jagsonpal Pharmaceuticals has signed a Business Transfer Agreement to acquire Resilient Cosmeceuticals' India business for ₹24 crore. The deal, expected to close within 45 days, will be funded through internal accruals. This acquisition expands Jagsonpal's portfolio in Pharmaceuticals, Nutritional, and Cosmetic products, strengthening its position in Gynaecology and Dermatology. The move is set to enhance Jagsonpal's market presence, particularly in Maharashtra, Karnataka, and Kerala, and is projected to improve its market ranking from 75th to 71st in the pharmaceutical sector.
21Feb 25
Jagsonpal Pharmaceuticals Faces FDA Warning: Potential Impact on US Sales
Jagsonpal Pharmaceuticals has received a warning letter from the U.S. FDA dated February 5, 2025, citing CGMP violations and registration issues at a contract manufacturing facility. The company disclosed potential sales loss of 35 million INR (1.46% of annual sales) due to this warning. Jagsonpal currently supplies only one OTC API to the U.S. market. The company informed stock exchanges on February 21, 2025, in compliance with SEBI regulations.